Please assess the completion status of the following clinical trial:

Trial Title: Uric Acid Reduction as a Novel Treatment for Pediatric Chronic Kidney Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Chronic Kidney Disease stage 1-5~* Hyperuricemic (UA \>= 5.5 mg/dL)~Exclusion Criteria:~* Contraindication to Allopurinol~* Elevated baseline liver function tests~* Receiving acute or chronic dialysis~* Primary metabolic disorder~* Sickle cell disease~* Autosomal Dominant Polycystic Kidney Disease~* Cystinosis~* Bartter or Gitelman Disease~* Pregnant or nursing

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 20 Years
- Healthy Volunteers: f

Study Arms:
- Allopurinol (Type: ACTIVE_COMPARATOR): Allopurinol will be administered to this treatment arm group for 6 months. Participants will receive the lowest FDA recommended dose for weight, and will be titrated upwards to achieve the goal uric acid level of 3-5 mg/dL throughout the trial.
- Standard of Care Control (Type: NO_INTERVENTION): The treatment arm will be compared to a standard of care arm.

Based on this trial design, predict the completion outcome and termination type (if applicable).